Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation

Clear cell renal cell carcinoma (ccRCC) represents the most common subtype of renal cell carcinoma (RCC). In spite of recent advances in the treatment armamentarium and outcomes with the combined use of immune checkpoint and angiogenesis inhibitors, prediction of responses and selection of patients...

Descripción completa

Detalles Bibliográficos
Autor principal: Vlachostergios, Panagiotis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Codon Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497900/
https://www.ncbi.nlm.nih.gov/pubmed/32983840
http://dx.doi.org/10.15586/jkcvhl.2020.135

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7497900/
https://www.ncbi.nlm.nih.gov/pubmed/32983840
http://dx.doi.org/10.15586/jkcvhl.2020.135

Ejemplares similares